About Solid Biosciences
Solid Biosciences is a company based in Cambridge (United States) founded in 2014. Solid Biosciences has raised $92.5 million across 7 funding rounds from investors including Biogen, Janus Henderson Investors and RTW Investments. The company has 100 employees. Solid Biosciences has completed 1 acquisition, including AAVANTIBio. Solid Biosciences offers products and services including Gene Therapy Candidates and Genetic Regulators Library. Solid Biosciences operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, Spark Therapeutics, MiRagen and Lundbeck, among others.
- Headquarter Cambridge, United States
- Employees 100
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website solidbio.com
- Social LinkedIn X
- Legal Name Solid Biosciences Inc.
- Net Profit-$174.32 M (USD)-39.8as on Dec 31, 2025
- EBITDA-$177.57 M (USD)-39.52as on Dec 31, 2025
- Total Equity Funding$92.5M (USD)
in 7 rounds
- Latest Funding Round$240M (USD), Post-IPO
Mar 2026
- InvestorsBiogen
& 17 more
- Employee Count100
- Investments & Acquisitions
Products & Services of Solid Biosciences
Solid Biosciences offers a comprehensive portfolio of products and services, including Gene Therapy Candidates and Genetic Regulators Library.
Treatments targeting rare neuromuscular diseases
Tools to enhance gene therapy delivery methods
Funding Insights of Solid Biosciences
Solid Biosciences has successfully raised a total of $92.5M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $240 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $92.5M
- Total Rounds 7
- Last Round Post-IPO — $240M
- First Round $42.5M
(Nov 2015)
- Investors Count 18
All 7 funding rounds of Solid Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $240M | Post-IPO | – | – | |
| Jan 2024 | $108.9M | Post-IPO | – | – | |
| Dec 2020 | $90M | Post-IPO | – | – | |
| Oct 2020 | $40M | Post-IPO | – | – | – |
| Jul 2019 | $59.98M | Post-IPO | – | – | – |
| Mar 2017 | $50M | Series C | – | RA Capital Management, Bain Capital Life Sciences | |
| Nov 2015 | $42.5M | Series B | – | – |
18 investors in total: 18 institutional.
Investors in Solid Biosciences
Solid Biosciences has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, Janus Henderson Investors and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | – | baincapitallifesciences.com | Boston, United States | |
- | – | aspirecapital.com | - | |
Investment services are offered by Ikarian Capital for various sectors. | – | ikariancapital.com | Dallas, United States | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | – | foresitecapital.com | New York, United States | |
- | – | vestalpoint.com | - |
Investor details for Solid Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Solid Biosciences
44 people are tracked at Solid Biosciences (27 in leadership, 8 in board & advisors, 9 in team); the tracked headcount is 100.
| Name | Role | Group |
|---|---|---|
Bo Cumbo | President & CEO | Leadership |
Ty Howton | Chief Administrative Officer | Leadership |
Jessie Hanrahan | Chief Regulatory And Preclinical Operations Officer | Leadership |
Paul Herzich | CTO | Leadership |
Kathleen Kelly | Senior Director, Corporate Controller | Leadership |
Melanie Von Schimmelmann | Vice President, Portfolio And Program Management | Leadership |
Brian Hughes | Vice President | Head Of Human Resources | Leadership |
Resham Banga | Associate Director | Leadership |
Elizabeth Crawford | Senior Director, Portfolio And Program Management | Leadership |
Kevin T. | Chief Financial Officer | Leadership |
Sarah Stelzleni | Executive Director, Regulatory | Leadership |
Carol Lahiff | Associate Director, Fp&a | Leadership |
Bigue N.konte | Associate Director Fp&a | Leadership |
Nilay Patel | Director, Vector Supply And Innovation | Leadership |
Keith Clark | Senior Director Information Technology | Leadership |
Oyinade Adefuye | Director Of Program Management | Leadership |
Nicoleta Stoicea | Medical Director, Clinical Development | Leadership |
Allison Bogosian | Svp, Head Of Human Resources & Administrative Operations | Leadership |
Kevin Tan | CFO | Leadership |
Ryan Cole | Director Of Accounting | Leadership |
24 more people are available in the full profile.
Complete people profiles for Solid Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Solid Biosciences
Solid Biosciences is a publicly listed company on the NASDAQ with ticker symbol SLDB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Jan 2018
- Listed onNASDAQ: NASDAQ
- Listed entitySolid Biosciences Inc.
- Exchange sectorHealth technology
- ISINUS83422E2046
- Share price$6.82 (-0.44% on the day) · 2026-10-08
- Market capitalisation$731.3M
- EPS (diluted, trailing year)$-1.91
- Volume (last session)1,308,109
Financials of Solid Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$174.3M | -$177.6M |
| 2024 | – | -$124.7M | -$127.3M |
| 2023 | – | -$96.0M | -$101.7M |
| 2022 | $8.1M | -$86.0M | -$92.0M |
| 2021 | $13.6M | -$72.2M | -$69.3M |
Detailed financial statements for Solid Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Solid Biosciences
Solid Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AAVANTIBio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene transfer therapies for neuromuscular diseases are developed. | aavantibio.com | Gainesville, United States | 2017 | Sep 2022 | $75M |
Complete acquisition details for Solid Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Solid Biosciences
5 dated milestones of Solid Biosciences across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Solid Biosciences is founded.
- Funding First funding round of $42.5M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires AAVANTIBio.
- Funding Latest funding round, Post-IPO, of $240.0M.
Competitors of Solid Biosciences
Solid Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, Spark Therapeutics, MiRagen and Lundbeck, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| lundbeck.com | 1915 | Copenhagen, Denmark | – | 393 | Drugs for CNS disorders are developed and advanced. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies |
Detailed competitors of Solid Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Solid Biosciences
The website of Solid Biosciences (solidbio.com) receives about 8.2K visits a month and ranks #2,087,502 among all websites worldwide, #2,850 in Biotechnology and Pharmaceuticals.
- Monthly visits8.2K
▼ 4.2% vs previous month
- Unique visitors4K
per month
- Global rank#2,087,502
among all websites
- Category rank#2,850
Health · Biotechnology and Pharmaceuticals
- Bounce rate30%
- Pages per visit2.9
- Average visit2 min 49 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Solid Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medigene.com | 100% | 1.1K | #13,562,665 | View details | |
cgtlive.com | cgtlive.com | 80% | – | #1,198,562 | – |
| fiercebiotech.com | 80% | 858.3K | #81,022 | View details |
Latest news on Solid Biosciences
Complete news archive for Solid Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Solid Biosciences
10 companies that operate in the same segment as Solid Biosciences (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Solid Biosciences
Solid Biosciences was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Solid Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Solid Biosciences is a funded company, having raised a total of $92.5M across 7 funding rounds to date. The company's 1st funding round was a Series B of $42.5M, raised on Nov 2015.
Solid Biosciences has 100 employees.
Solid Biosciences was founded in 2014 and is headquartered in Cambridge, United States. Focus is placed on biotechnology, specifically the development of gene therapy solutions for Duchenne muscular dystrophy. The primary candidate, SGT-001, features Microdystrophin, a synthetic dystrophin gene engineered to stabilize muscle membranes and the dystrophin-glycoprotein complex. A soft wearable device is also produced to support mobility and maintain muscle function for patients.
Solid Biosciences's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and Sana Biotechnology.
Solid Biosciences offers Gene Therapy Candidates and Genetic Regulators Library.
Yes, Solid Biosciences is publicly traded on NASDAQ under the ticker symbol SLDB.
Solid Biosciences has made 1 acquisition, including AAVANTIBio.
Solid Biosciences has 18 investors. Key investors include Biogen, Janus Henderson Investors, RTW Investments, RA Capital, and Perceptive Advisors.
Solid Biosciences operates through Solid Biosciences Inc..